mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03288350 |
|
Recruitment Status :
Recruiting
First Posted : September 20, 2017
Last Update Posted : March 22, 2018
|
Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Information provided by (Responsible Party):
Thierry Alcindor, McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2023 |